Relevant bibliographies by topics / Plasma Cell Leukemi

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Plasma Cell Leukemi'

Author: Grafiati
Published: 25 January 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Plasma Cell Leukemi.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Plasma Cell Leukemi"

1

Ishida, Yoji, Kazunori Murai, Kohei Yamaguchi, et al. "Pharmacokinetic (PK) and Pharmacodynamic (PD) Study Of Dasatinib In Chronic Phase Of Newly Diagnosed Chronic Myeloid Leukemia (CML-CP)." Blood 122, no. 21 (2013): 4031. http://dx.doi.org/10.1182/blood.v122.21.4031.4031.

Full text
Abstract:
Abstract Purpose Dasatinib is a novel kinase inhibitor of BCR-ABL and SRC family kinases. Dasatinib has shown promising anti-leukemic activity in chronic myeloid leukemi (CML). Tounderstand how to administer dasatinib with best efficacy and less adverse events, the pharmacokinetic (PK) properties of dasatinib and the relationship of PK and pharmacodynamic (PD) characteristics were investigated in newly diagnosed CML-chronic phase (CP) patients. Methods and Materials The PK analysis of dasatinib: The plasma concentrations of dasatinib (1, 2, 4 hr after taking dasatinib post 28 days) were determ
APA, Harvard, Vancouver, ISO, and other styles
2

I, Jamal. "Plasma Cell Leukemia: An Overview." Haematology International Journal 5, no. 1 (2021): 1–2. http://dx.doi.org/10.23880/hij-16000175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sumeet, Bajaj Preeti, Kasture Jyoti Uttamrao, and Shah Balbir Singh. "Plasma Cell Leukemia: Clinicopathological Profile of Five Cases." Indian Journal of Forensic Medicine and Pathology 9, no. 3 (2016): 189–91. http://dx.doi.org/10.21088/ijfmp.0974.3383.9316.18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hudák, Renáta, Ildikó Beke Debreceni, Ivett Deák, et al. "Laboratory characterization of leukemic cell procoagulants." Clinical Chemistry and Laboratory Medicine (CCLM) 55, no. 8 (2017): 1215–23. http://dx.doi.org/10.1515/cclm-2017-0021.

Full text
Abstract:
Abstract Background: In acute myeloid leukemias, there is an increased chance to develop thrombotic disorders. We hypothesized that in addition to leukemic promyelocytes, monocytic leukemia cells may also have a higher procoagulant activity. Methods: Fibrin formation was assessed by a one-stage clotting assay using a magnetic coagulometer. The thrombin generation test (TGT) of magnetically isolated normal human monocytes, intact leukemic cells and their isolated microparticles was performed by a fluorimetric assay. Phosphatidylserine (PS) expression of leukemic cells and microparticle number d
APA, Harvard, Vancouver, ISO, and other styles
5

S, Nibhoria. "Plasma Cell Leukemia–A Case Report and Review of Literature." Cytology & Histology International Journal 5, no. 1 (2021): 1–4. http://dx.doi.org/10.23880/chij-16000133.

Full text
Abstract:
Plasma cell leukaemia (PCL) is one of the most aggressive and rarest forms of plasma cell dyscrasia. As prognosis is very poor, it is very important to recognize this entity sufficiently early so that one can offer combination chemotherapy at the earliest which can prolong survival.
APA, Harvard, Vancouver, ISO, and other styles
6

Keita, Mohamed, Sokhna Aissatou Touré, Elimane Seydi Bousso, et al. "PLASMA CELL LEUKEMIA: AN AGGRESSIVE DISEASE, A CAUSE OF DIAGNOSTIC ERROR." International Journal of Medical Science and Dental Health 10, no. 04 (2024): 15–20. http://dx.doi.org/10.55640/ijmsdh-10-04-23.

Full text
Abstract:
Plasma cell leukemia (LP) is a rare and aggressive plasma cell tumor that manifests as significant clonal expansion of plasma cells in the bone marrow and peripheral blood. It is considered primary when it presents at initial diagnosis and secondary when it occurs in patients with pre-existing multiple myeloma (MM). Because of the high frequency of extramedullary injuries, plasma cell leukemia is a major source of diagnostic error that can lead to fatality. We report a case of plasma cell leukemia diagnosed at the clinical haematology department of the CNTS in Dakar (Senegal).
APA, Harvard, Vancouver, ISO, and other styles
7

Zhang, Ke, Hagop M. Kantarjian, Wanlong Ma, et al. "Use of Ubiquitin-Proteasome System Profiling for Differentiating Between Various Leukemic Processes." Blood 114, no. 22 (2009): 4712. http://dx.doi.org/10.1182/blood.v114.22.4712.4712.

Full text
Abstract:
Abstract Abstract 4712 The ubiquitin-proteasome system (UPS) plays a major role in cell homeostasis in normal and neoplastic states. Expression and function of the UPS system vary with the specific characteristics of individual cell types, suggesting that determination of UPS “signatures” could be useful in identifying various cell populations. Since direct analysis of cancer cells is often problematic, even in hematologic diseases, we explored the potential of using UPS signatures in plasma to differentiate between various leukemias. We first analyzed plasma UPS profiles of patients with acut
APA, Harvard, Vancouver, ISO, and other styles
8

Heumann, D., G. Losa, C. Barras, A. Morell, and V. von Fliedner. "Characterization of acute undifferentiated leukemia by combined analysis of plasma membrane-associated gamma-glutamyltranspeptidase and soluble terminal transferase." Blood 66, no. 2 (1985): 255–58. http://dx.doi.org/10.1182/blood.v66.2.255.bloodjournal662255.

Full text
Abstract:
gamma-Glutamyltranspeptidase (gamma-GT) is a plasma membrane-associated enzyme present in blasts of certain acute leukemias. We analyzed 90 cases of undifferentiated and differentiated acute leukemias for gamma- GT, using a colorimetric assay. Blasts of all patients with common acute lymphoblastic leukemia (ALL) and T-ALL were negative for gamma-GT (less than 5 units). In contrast, gamma-GT was significantly elevated in acute myeloblastic or monoblastic leukemia blasts (P less than .001). In 16 cases of acute undifferentiated leukemia (AUL) studied, the levels of gamma-GT ranged from 0 to 93 u
APA, Harvard, Vancouver, ISO, and other styles
9

Heumann, D., G. Losa, C. Barras, A. Morell, and V. von Fliedner. "Characterization of acute undifferentiated leukemia by combined analysis of plasma membrane-associated gamma-glutamyltranspeptidase and soluble terminal transferase." Blood 66, no. 2 (1985): 255–58. http://dx.doi.org/10.1182/blood.v66.2.255.255.

Full text
Abstract:
Abstract gamma-Glutamyltranspeptidase (gamma-GT) is a plasma membrane-associated enzyme present in blasts of certain acute leukemias. We analyzed 90 cases of undifferentiated and differentiated acute leukemias for gamma- GT, using a colorimetric assay. Blasts of all patients with common acute lymphoblastic leukemia (ALL) and T-ALL were negative for gamma-GT (less than 5 units). In contrast, gamma-GT was significantly elevated in acute myeloblastic or monoblastic leukemia blasts (P less than .001). In 16 cases of acute undifferentiated leukemia (AUL) studied, the levels of gamma-GT ranged from
APA, Harvard, Vancouver, ISO, and other styles
10

Alitalo, Riitta, Ross Stephens, Antti Vaheri, and Satu Mustjoki. "Blast Cell-surface and Plasma Soluble Urokinase Receptor in Acute Leukemia Patients: Relationship to Classification and Response to Therapy." Thrombosis and Haemostasis 81, no. 05 (1999): 705–10. http://dx.doi.org/10.1055/s-0037-1614558.

Full text
Abstract:
SummaryPlasminogen activation in leukemia has been less well characterized than in other malignancies. However, the increased tendency to bleeding and tissue infiltration by leukemic cells are processes in which plasminogen activation may be involved. We have examined plasma and the peripheral blood mononuclear cell fraction from 80 patients including 53 patients with newly diagnosed acute leukemia and 27 patients with other hematological disorders as well as 21 healthy controls. In 28 of 29 examined patients with acute myeloid leukemia (AML) and in two of three patients with hybrid leukemia w
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Plasma Cell Leukemi"

1

Champion, Ophélie. "Role of the mitochondrial channel VDAC2 in the regulation of apoptosis effector proteins BAK and BAX in Multiple Myeloma." Electronic Thesis or Diss., Nantes Université, 2024. http://www.theses.fr/2024NANU1030.

Full text
Abstract:
Le Myélome Multiple (MM) est une hémopathie maligne rare où des plasmocytes tumoraux envahissent la moelle osseuse. Malgré les avancées thérapeutiques, les patients rechutent, notamment par échappement à l’apoptose. Ce travail vise à comprendre le mécanisme de mort cellulaire mis en place par VDAC2, qui appartient à la famille des canaux mitochondriaux voltage-dépendants avec VDAC1 et VDAC3. Les 3 VDACs sont exprimés de manière hétérogène dans le MM. Une faible expression de VDAC2 est associée à une survie globale défavorable dans 764 échantillons d’une cohorte de MM. De plus, l'expression de
APA, Harvard, Vancouver, ISO, and other styles
2

Manthri, Sukesh, Haroon Rehman, Rabia Zafar, and Kanishka Chakraborty. "A Rare Case of Non-Producing Primary Plasma Cell Leukemia." Digital Commons @ East Tennessee State University, 2019. https://dc.etsu.edu/asrf/2019/schedule/89.

Full text
Abstract:
Non-Secretory Multiple Myeloma (NSMM) is characterized by typical morphological and pathological multiple myeloma (MM) characteristics and the absence of an M-protein on immunofixation electrophoresis with estimated prevalence of 3%. Among the NSMM cases there is a subset in which no cytoplasmic Immunoglobulin synthesis is detected, and this entity is called ‘’Non-Producing’’ Multiple Myeloma (NPMM). Plasma cell leukemia (PCL) is an aggressive form of MM characterized by high levels of abnormal plasma cells circulating in the peripheral blood. We present a rare case of non-producing variant of
APA, Harvard, Vancouver, ISO, and other styles
3

Lionetti, M. "BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNA EXPRESSION SIGNATURES IN PRIMARY PLASMA CELL LEUKEMIA." Doctoral thesis, Università degli Studi di Milano, 2013. http://hdl.handle.net/2434/217172.

Full text
Abstract:
Purpose: Plasma cell leukemia (PCL) is a very aggressive and rare hematological malignancy that can be distinguished into primary (pPCL), originating de novo, or secondary (sPCL), arising as a leukemic transformation of multiple myeloma (MM). Genomic and clinical differences between pPCL and MM have been demonstrated, mainly based on retrospective studies. This study was aimed at investigating the involvement of miRNAs in pPCL and their possible relationship with higher tumor aggressiveness. Experimental design: MiRNA expression profiles were analyzed in highly-purified malignant plasma cells
APA, Harvard, Vancouver, ISO, and other styles
4

Barbieri, M. "HIGH-THROUGHPUT SEQUENCING FOR THE IDENTIFICATION OF DIS3 MUTATIONS IN MULTIPLE MYELOMA." Doctoral thesis, Università degli Studi di Milano, 2015. http://hdl.handle.net/2434/259303.

Full text
Abstract:
Multiple myeloma (MM) is an incurable malignancy of mature plasma cells (PCs), and its pathogenesis is only partially understood. Recently, whole exome sequencing studies have identified mutations of DIS3, a catalytic subunit of the human exosome complex, in about 10% of MM patients. This study was aimed at investigating the spectrum of DIS3 mutations indifferent stages of plasma cell dyscrasia. To analyze DIS3 mutations, we investigated by next generation sequencing (NGS) a retrospective cohort of 130 cases with MM at onset and 17 at relapse (of whom 15 were also tested at onset). Moreover,
APA, Harvard, Vancouver, ISO, and other styles
5

Adhinaveni, Ramesh. "Molecular analysis of different clinical presentations of chronic lymphocytic leukemia reveals novel molecular predictors and molecular heterogenety of different anatomical compartments." Doctoral thesis, Università del Piemonte Orientale, 2022. http://hdl.handle.net/11579/144065.

Full text
Abstract:
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are different manifestation of the same lymphoproliferative disease. Our study aims at evaluating molecular markers that predispose to chemorefractoriness in CLL and to identify molecular landscape of the different anatomical compartments of SLL. Fludarabine, cyclophosphamide, and rituximab (FCR) is the most effective chemoimmunotherapy regimen for young and fit CLL patients devoid of TP53 disruption. A cohort of 287 patients receiving first-line FCR was analyzed by next generation sequencing (NGS). By univariate analysis,
APA, Harvard, Vancouver, ISO, and other styles
6

Jouan, Alain. "Le complexe NADPH-oxydase producteur d'ions superoxyde des neutrophiles : étude immunochimique des facteurs cytosoliques d'activation." Université Joseph Fourier (Grenoble), 1995. http://www.theses.fr/1995GRE10154.

Full text
Abstract:
Le complexe nadph-oxydase producteur d'ions superoxyde des neutrophiles est compose de sous-unites cytosoliques et membranaires qui s'assemblent au cours du processus d'activation de l'enzyme. La proteine g monomerique rac stimule considerablement l'activation. Nous avons produit des anticorps monoclonaux, polyclonaux et anti-peptides contre les constituants cytosoliques de ce complexe (facteurs cytosoliques), et contre le systeme des proteine g monomeriques associees au complexe. Les anticorps nous ont permis de mettre au point une technique elisa hypersensible de detection et de dosage des d
APA, Harvard, Vancouver, ISO, and other styles
7

Burianová, Ilona. "Inhibitory histondeacetyláz v léčbě plazmocelulární leukemie: vliv mikroprostředí kostní dřeně." Doctoral thesis, 2016. http://www.nusl.cz/ntk/nusl-351282.

Full text
Abstract:
Multiple myeloma and its aggressive variant, plasma cell leukemia, are still considered to be incurable diseases despite the progressive treatment approaches comprising novel drugs. This can be attributed to the presence of the bone marrow microenvironment which plays an important role in drug resistance of myeloma cells. Hematopoietic cell lines derived from hematologic malignancies are suitable models for the study of etiopathogenesis of these malignant diseases and for testing new potential drugs. Establishment of these cell lines is still considered to be coincidental and rare event. The f
APA, Harvard, Vancouver, ISO, and other styles
8

CHAO, YA-LI, and 趙亞麗. "Identification of diabete-related plasma and liver protein markers by using post-translational proteomic approaches and a proteomic approach to decipher the growth inhibition and killing mechanism of nano-gold particles on human leukemia cells." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/09122331437848612324.

Full text
Abstract:
碩士<br>輔仁大學<br>生命科學系碩士班<br>97<br>In this study, we utilized proteomic approaches to investigate the differentially expressed plasma protein related to diabetes. The streptozotocin (STZ) diabetic rats were utilized for investigation. Using high fat diet to induce the diabete-like phenotype, the STZ treated and the control rat were examined for the blood sugar level and regrouped for proteomic analysis. By employing our developed affinity chromatography, the total proteome as well as the phosphoproteome and glycoproteome from the rat plasma samples were purified and examined. Briefly, albumin, vi
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Plasma Cell Leukemi"

1

Steensma, David P. Malignant Hematology. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0296.

Full text
Abstract:
The hematologic neoplasms include lymphoproliferative disorders (eg, chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL], large granular lymphocyte leukemia, hairy cell leukemia [HCL], Hodgkin lymphoma, non-Hodgkin lymphoma), plasma cell disorders (multiple myeloma, light chain amyloidosis, Waldenström macroglobulinemia, POEMS syndrome, heavy chain disease, plasmacytoma), chronic myeloid neoplasms (chronic myeloid leukemia, the BCR/ABL-negative myeloproliferative neoplasms, myelodysplastic syndromes), and acute leukemia (acute myeloid leukemia, acute lymphocytic leukemia). In a
APA, Harvard, Vancouver, ISO, and other styles
2

Carton, James. Haematopathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0015.

Full text
Abstract:
This chapter discusses haematopathology, including iron deficiency anaemia, anaemia of chronic disease, megaloblastic anaemias, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, thalassaemias, sickle-cell disorders, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), von Willebrand disease, haemophilia, thrombophilia, acute B-lymphoblastic leukaemia, acute myeloid leukaemias, chronic lymphocytic leukaemia (CLL), chronic myelogenous leukaemia, polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF), myelodyspl
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Bone and soft tissue malignancies. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.003.0025.

Full text
Abstract:
Haematological malignancies examines the epidemiology, genetics, clinical presentation and classification of these diseases, and presents current treatment approaches for each. First are the acute leukaemias, and the management of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Chronic myeloid leukaemia, its genetics and sensitivity to tyrosine kinase inhibitors, is described. Myelodysplastic syndromes and their management, are followed by chronic lymphoid leukaemias, a large heterogeneous group of diseases, and their treatment. Hodgkin lymphoma, its pathology and presen
APA, Harvard, Vancouver, ISO, and other styles
4

Adam, Sheila, Sue Osborne, and John Welch. Haematological problems. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199696260.003.0012.

Full text
Abstract:
This chapter discusses specific haematological disorders that require the patient to be admitted to the critical care unit. It describes the normal physiology of blood cells, clotting mechanisms, and fibrinolysis, and the management of related conditions such as thrombocytopenia, leukaemia, and clotting disorders such as disseminated intravascular coagulation. It also includes the management of the critical care patient with haematological malignancy. Specific therapies such as plasma exchange and anticoagulation therapy are discussed in detail and the monitoring of coagulation tests is explai
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Plasma Cell Leukemi"

1

Joseph, Nisha S., Amarendra K. Neppalli, and Ajay K. Nooka. "Plasma Cell Leukemia." In Personalized Therapy for Multiple Myeloma. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-61872-2_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hayman, Suzanne R. "Plasma Cell Leukemia." In Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-662-08885-2_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Joseph, Nisha S., and Sagar Lonial. "Plasma Cell Leukemia." In Neoplastic Diseases of the Blood. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64263-5_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gonsalves, Wilson I., and Shaji K. Kumar. "Plasma Cell Leukemia." In Biology and Management of Unusual Plasma Cell Dyscrasias. Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4419-6848-7_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eltorai, Ibrahim M. "Plasma Cell Leukemia (PCL)." In Rare Diseases and Syndromes of the Spinal Cord. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-45147-3_116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gertz, Morie A., Laura Rosinol, and Joan Bladé. "Plasma Cell Leukemia and Extramedullary Plasmacytoma." In Hematologic Malignancies. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-25586-6_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Drappatz, Jan, and Kurt A. Jaeckle. "Neurological Complications of Plasma Cell Disorders." In Lymphoma and Leukemia of the Nervous System. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-7668-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hashmi, Shahrukh. "Hematological Malignancies in the UAE." In Cancer Care in the United Arab Emirates. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-6794-0_38.

Full text
Abstract:
AbstractHematologic malignancies make up a substantial portion of overall cancers, and unfortunately, the incidence of hematologic malignancies continues to grow in developed countries. These encompass both inherited and acquired cancers, though complicating the differentiation is the fact that some of the primary immunodeficiencies and bone marrow failure syndromes can lead to the development of leukemia and myelodysplastic syndrome as well, besides lymphomas. Plasma cell dyscrasias are also a complicated group of conditions that include, at one spectrum, AL amyloidosis, which can be rapidly
APA, Harvard, Vancouver, ISO, and other styles
9

Zegadlo, M., M. Matysiak, and M. Ochochka. "Plasma Cell Leukemia in a 7-month-old Infant." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion. Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-71960-8_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khojasteh, Ali. "Cardiac Disorders in Leukemias and Plasma-Cell Dyscrasias." In Cancer and the Heart. Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4612-4898-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Plasma Cell Leukemi"

1

Falang, A., G. M. Alessio, M. Donati, and T. A. Barbui. "DISSEMINATED INTRAVASCULAR COAGULATION (DIC) AND ACUTE LEUKEMIA:IDENTIFICATION OF A NEW CELLULAR PROCOAGULANT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643661.

Full text
Abstract:
There is an enhanced incidence (&gt;50%) of severe coagulopathy in association with several types of acute leukemias. Cell associated procoagulants are considered important in this context. So far only a Tissue Factor (TF)-type procoagulant has been described in leukemic cells. We have set up here the experimentalconditions to identify other possible cellular procoagulants in leukemia. We have tested blast cell extracts from 21 patients with 5 different cytological subtypes (from Ml to M5 of acute non lymphoid leukemia (ANLL), according to theFAB classification, in order to assay whether they
APA, Harvard, Vancouver, ISO, and other styles
2

Thiyagarajan, Magesh. "Portable Plasma Biomedical Device for Cancer Treatment." In ASME 2011 6th Frontiers in Biomedical Devices Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/biomed2011-66030.

Full text
Abstract:
This research study examined the effect of non-thermal portable atmospheric air plasma system on leukemia cancer cells. Acute monocytic leukemia cells (THP-1) were exposed to atmospheric pressure non-thermal plasma. To assess death caused by plasma exposure, cells were subjected to trypan blue exclusion assays and a kill-curve and assessment of death overtime were compiled using data from the assays. In addition to this, DNA was harvested from treated and untreated samples to determine if apoptotic ladders were present. Results have indicated that non-thermal plasma can cause cell death in THP
APA, Harvard, Vancouver, ISO, and other styles
3

Gamba, G., L. Dezza, N. Montani, G. Gangale, G. Gangale, and E. Ascari. "EFFECT OF INTERFERON GAMMA ON PROCOAGULANT ACTIVITY FROM HUMAN PROMYELOCYTIC CELL LINE (HL 60)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643662.

Full text
Abstract:
Interferon gamma (IFN), a lymphokine acting as biological response modifier, can induce morphological and phenotypic differentiation of some leukemic cell lines, specially along the monocytic pathway.Furthermore, myeloid leukemic cells and normal monocytes have been demonstrated to possess procoagulant activity (PCA).The aim of this study was to investigate the modulation of PCA induced by treatment with IFN on human promyelocytic cells from HL 60 cell line.Cells were cultured in suspension for 5days in RPMI 1640 medium supplemented with 10% fetal calf serum in the absence or in the presence o
APA, Harvard, Vancouver, ISO, and other styles
4

Esumi, N., S. Todo, and S. Imashuku. "INTERACTION BETWEEN HEMOSTATIC COMPONENTS AND TUMOR CELLS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643202.

Full text
Abstract:
Involvement of platelets and coagulation systems in the hematogenous metastasis of tumor cells has been suggested from in vivo and in vitro studies, however, there is still controversy about the exact role of hemostasis in metastasis. To date, at least three types of platelet aggregating mechanisms and three types of tumor cell procoagulants have been reported in different tumor cells.We investigated platelet aggregating activity (PAA), procoagulant activity (PCA) and the relationship between these two activities, using eight human neuroblastoma cell lines, three human leukemia cell lines and
APA, Harvard, Vancouver, ISO, and other styles
5

Thiyagarajan, M., X. Gonzales, H. Anderson, and M. Norfolk. "Non-thermal plasma induction of preprogrammed cell death in monocytic leukemia cells." In 2012 IEEE 39th International Conference on Plasma Sciences (ICOPS). IEEE, 2012. http://dx.doi.org/10.1109/plasma.2012.6383688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Berthier, R., A. Duperray, O. Valiron, M. Prenant, I. Newton, and A. Schweitzer. "MEGAKARYOCYTIC DEVELOPMENT IN LIQUID CULTURES OF CRYOPRESERVED LEUKOCYTE STEM CELL CONCENTRATES FROM CHRONIC MYELOGENOUS LEUKEMIA PATIENTS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644622.

Full text
Abstract:
The proliferation and differentiation of human megakaryocytes in liquid culture has been obtained using cryopreserved light density blood cell concentrates from chronic myelogenous leukemia (CML) patients. These cryopreserved leukocytes concentrates contain a large number of viable granulo-monocytic, erythroid and megakaryocytic committed stem cells. A high number of spontaneous megakaryocytic colonies was observed in semisolid cultures plated with the CML leukocytes concentrates. A liquid culture system using RPMI 1640 supplemented with 20% human plasma (HP) has been defined where maturing me
APA, Harvard, Vancouver, ISO, and other styles
7

Barekzi, N., and M. Laroussi. "Low temperature atmospheric pressure plasma kills leukemia cells." In 2012 IEEE 39th International Conference on Plasma Sciences (ICOPS). IEEE, 2012. http://dx.doi.org/10.1109/plasma.2012.6383691.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Anderson, Heather, Xavier Gonzales, Samantha Valdez, and Magesh Thiyagarajan. "Activation of apoptotic cell death in human myeloid leukemia cells by RNS: A novel antitumor approach using resistive barrier plasma." In 2013 IEEE 40th International Conference on Plasma Sciences (ICOPS). IEEE, 2013. http://dx.doi.org/10.1109/plasma.2013.6634817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Paparo, Sabrina Marie, Rebeca Mendoza, Robert Chitren, et al. "Investigating the Therapeutic Potential of Soursop in Treating Hematologic Malignancies." In 28th Annual Rowan-Virtua Research Day. Rowan University Libraries, 2024. http://dx.doi.org/10.31986/issn.2689-0690_rdw.stratford_research_day.129_2024.

Full text
Abstract:
Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) are hematologic malignancies that originate in the bone marrow and account for approximately 1.3% and 2% of cancer cases, respectively. AML is characterized by an accumulation of myeloblasts, or immature myeloid cells, that have the potential to spread to the peripheral blood. There is an uncontrolled proliferation of plasma cells in the bone marrow in MM. While the current treatment options for both AML and MM show promise in achieving initial remission, it is unfortunately common for patients to experience relapse and develop drug resist
APA, Harvard, Vancouver, ISO, and other styles
10

Narahara, N., H. Sadakata, T. Uchiyama, et al. "MECHANISM OF ACTIVATION OF BLOOD COAGULATION BY LEUKOCYTE PROCOAGULANT ACTIVITY." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643161.

Full text
Abstract:
To investigate the process of activation mechanism of blood coagulation by leukocytes, binding of radiolabelled Factor X and the activation of Factor X on the cell surface of leukocytes were studied by using cultured leukemia cell line, Molt-4 cells. Cells were cultured in RPMI 1640 medium with 10% inactivated fetal, calf serum at a concentration of 1x106cells/ml. After 6 hours' stimulation with 1 ug/ml of endotoxin(LPS: Escherichia coli 026:B6), cells were separated by centrifugation, washed three times with Tris containing NaCl buffer(pH 7.5, TBS), and then suspended in TBS containing 0.5% b
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Plasma Cell Leukemi' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography